Grace Therapeutics (GRCE) KOL Event summary

Introduction and agenda

• Event focused on GTx-104, a novel injectable nimodipine for aneurysmal subarachnoid hemorrhage (aSAH), with forward-looking statements and a Q&A session planned.

• Agenda included disease overview, challenges with current oral nimodipine, and market opportunity for GTx-104.

KOL background and credentials

• Dr. Abhishek Ray: neurosurgeon at University Hospitals, Case Western Reserve, with extensive experience in cerebrovascular surgery and clinical trials.

• Dr. Andrew Webb: neurocritical care pharmacist at MGH, involved in patient care, medication delivery, and hospital formulary decisions.

Market insights and analysis

• aSAH is a severe, often fatal condition with high pre-hospital and in-hospital mortality; incidence increases with age, especially in women over 55.

• Oral nimodipine is the only FDA-approved drug for aSAH but has significant limitations: poor bioavailability, high PK variability, frequent hypotension, and administration challenges in critically ill patients.

• Up to 50% of patients may not tolerate or receive full oral dosing due to dysphagia, GI intolerance, or hemodynamic instability.

• Less than half of patients receive the full recommended course, impacting outcomes.